









Markets
/
Stocks
/
nasdaq-pmn
/

ProMIS Neurosciences Inc

PMN

12.730USD

-0.370-2.82%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

27.40MMarket Cap

LossP/E TTM



ProMIS Neurosciences Inc

12.730

-0.370-2.82%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ProMIS Neurosciences Inc

Currency: USD Updated: 2026-02-06

Key Insights

ProMIS Neurosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 93 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 81.38.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ProMIS Neurosciences Inc's Score

Industry at a Glance

Industry Ranking

93 / 392

Overall Ranking

220 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

ProMIS Neurosciences Inc Highlights

StrengthsRisks

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is -0.63, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 395.46K shares, decreasing 29.85% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.47.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

81.375

Target Price

+521.18%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of ProMIS Neurosciences Inc is 6.95, ranking 180 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.95

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

ProMIS Neurosciences Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of ProMIS Neurosciences Inc is 8.64, ranking 31 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.63, which is -6143.43% below the recent high of 38.10 and -2347.80% above the recent low of -15.43.

Score

Industry at a Glance

Previous score

8.64

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 93/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of ProMIS Neurosciences Inc is 8.50, ranking 105 out of 392 in the Biotechnology & Medical Research industry. The average price target is 112.50, with a high of 237.50 and a low of 75.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

81.375

Target Price

+521.18%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

ProMIS Neurosciences Inc

PMN

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of ProMIS Neurosciences Inc is 7.44, ranking 72 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 19.06 and the support level at 7.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.51

Change

-0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.734

Buy

RSI(14)

60.051

Neutral

STOCH(KDJ)(9,3,3)

40.945

Sell

ATR(14)

1.899

High Vlolatility

CCI(14)

33.319

Neutral

Williams %R

60.469

Sell

TRIX(12,20)

2.745

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

14.286

Sell

MA10

12.931

Sell

MA20

10.669

Buy

MA50

9.041

Buy

MA100

9.936

Buy

MA200

11.895

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Ally Bridge Group NY LLC

242.35K

-2.80%

Shaf QIC LLC

207.39K

Jeremy M. Sclar 2012 Irrevocable Family Trust

148.42K

Jeremy M. Sclar 2012 Irrevocable Family Trust

148.42K

+129.40%

Armistice Capital LLC

118.98K

+39.13%

Title 19 ProMIS

97.40K

-19.35%

Crocker Mountain LLC

46.23K

Sphera Funds Management Ltd.

11.81K

-84.46%

Shafmaster (Madge K.)

8.00K

Kirwin (Patrick D)

4.04K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ProMIS Neurosciences Inc is 1.98, ranking 263 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is -0.08. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.